# Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma

> **NCT00317798** · PHASE1 · COMPLETED · sponsor: **University of Rochester** · enrollment: 18 (estimated)

## Conditions studied

- Drug/Agent Toxicity by Tissue/Organ
- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** anti-thymocyte globulin
- **DRUG:** sirolimus

## Key facts

- **NCT ID:** NCT00317798
- **Lead sponsor:** University of Rochester
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2011-08-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00317798

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00317798, "Antithymocyte Globulin and Sirolimus in Treating Patients With Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT00317798. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*